EGFR and non-small cell lung carcinoma: According to various clinical investigations, in non-small-cell lung cancer (NSCLC), EGFR-targeted therapy with gefitinib or erlotinib benefit was limited to NSCLC tumors bearing activating mutations of EGFR [40].